Parkinson’s disease is the second most common neurodegenerative disorder in the U.S. There are no proven strategies for preventing it or slowing its progression. But there is hope that a new treatment is on the horizon. This talk will outline the rationale for a large Phase 3 clinical neuroprotection trial in early stage Parkinson’s disease patients with the drug isradipine that is being sponsored by the National Institutes of Health. The core idea behind the trial is that some neurons in the brain act as look-outs or sentries – they are always watching for events that could hurt or help us – and that this constant vigilance causes them to wear out as we age. The goal of the drug therapy is to remodel these neurons in a way that allows them to ‘take a break’ and rest without compromising their ability to do their job in the less threatening, more predictable world we live in today!
D. James Surmeier is Nathan Smith Davis Professor and Chair of Physiology at the Feinberg School of Medicine at Northwestern University. He is a leading authority on fundamental mechanisms of Parkinson’s Disease, a member of various prestigious scientific societies, and recipient of numerous scientific awards. He directs the Morris K. Udall Center of Excellence for Parkinson’s Disease at Northwestern University, one of 9 elite, multidisciplinary centers funded by the National Institutes of Health to focus and causes and cures for Parkinson’s Disease.
UTSA Neurosciences Institute
Location: UTSA, Main Campus, UC Ballroom I
5:00p Reception | 5:30p Lecture
free parking* | public welcome
Visit http://neuroscience.utsa.edu for lecture details and free parking instructions!